<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18955">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02860130</url>
  </required_header>
  <id_info>
    <org_study_id>1407-004</org_study_id>
    <nct_id>NCT02860130</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)</brief_title>
  <official_title>Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baxter Healthcare Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to determine if an investigational new drug solution called
      Prismocitrate 18 lengthens extracorporeal circuit life in patients treated with continuous
      renal replacement therapy (CRRT). Patients who receive CRRT treatment with Prismocitrate 18
      as the anticoagulant will be compared to patients who receive CRRT treatment with no
      anticoagulation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to occurrence of selected PrismaflexÂ® System alarms/conditions</measure>
    <time_frame>Up to 120 hours post CRRT treatment initiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic blood iCa concentrations</measure>
    <time_frame>Baseline and up to 120 hours post CRRT treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-filter blood iCa concentrations</measure>
    <time_frame>Up to 120 hours post CRRT treatment initiation</time_frame>
    <description>Post-filter blood iCa concentrations will only be measured in the Prismocitrate 18 arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delivery of prescribed CRRT dose</measure>
    <time_frame>Up to 120 hours post CRRT treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prismocitrate 18 training assessment</measure>
    <time_frame>Prior to study use of Prismocitrate 18</time_frame>
    <description>Training to be completed on administration of Prismocitrate 18. Users, as delegated by the Principal Investigator, will be required to pass an assessment to demonstrate the understanding of how to use the solution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Bicarbonate</measure>
    <time_frame>Baseline and up to 120 hours post CRRT treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH</measure>
    <time_frame>Baseline and up to 120 hours post CRRT treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Base Excess</measure>
    <time_frame>Baseline and up to 120 hours post CRRT treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Total Calcium Concentration</measure>
    <time_frame>Baseline and up to 120 hours post CRRT treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Sodium</measure>
    <time_frame>Baseline and up to 120 hours post CRRT treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Anion Gap</measure>
    <time_frame>Baseline and up to 120 hours post CRRT treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Magnesium</measure>
    <time_frame>Baseline and up to 120 hours post CRRT treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Phosphate</measure>
    <time_frame>Baseline and up to 120 hours post CRRT treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Potassium</measure>
    <time_frame>Baseline and up to 120 hours post CRRT treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Chloride</measure>
    <time_frame>Baseline and up to 120 hours post CRRT treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number, Location, and Duration of Bleeding Events</measure>
    <time_frame>Up to 120 hours post CRRT treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood transfusions</measure>
    <time_frame>Up to 120 hours post CRRT treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 30 days post study CRRT treatment completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Baseline and up to 120 hours post CRRT treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Rate</measure>
    <time_frame>Baseline and up to 120 hours post CRRT treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temperature</measure>
    <time_frame>Baseline and up to 120 hours post CRRT treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>Baseline and up to 120 hours post CRRT treatment initiation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Regional Citrate Anticoagulation (RCA)</condition>
  <condition>Continuous Renal Replacement Therapy (CRRT)</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Prismocitrate 18</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No Regional Anticoagulation of CRRT Circuit</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prismocitrate 18</intervention_name>
    <description>Modality of CVVHDF</description>
    <arm_group_label>Prismocitrate 18</arm_group_label>
    <other_name>Regional Citrate Anticoagulation (RCA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Anticoagulation</intervention_name>
    <description>Modality of CVVHDF</description>
    <arm_group_label>No Regional Anticoagulation of CRRT Circuit</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient must be receiving medical care in an intensive care unit (ICU) (e.g., medical
             ICU, surgical ICU, cardiothoracic ICU, Trauma ICU, Mixed ICU, other).

          2. Adult patients with AKI or other serious conditions who require treatment with CRRT.

          3. Patients are expected to remain in the ICU and on CRRT for at least 72 hours after
             randomization.

          4. Patients already receiving standard-of-care CRRT must be randomized within 24 hours
             of initiation of their standard-of-care CRRT.

        Exclusion Criteria:

          1. Patients requiring systemic anticoagulation with antithrombotic agents for reasons
             other than CRRT. The exception is patients receiving subcutaneous heparin for deep
             vein thrombosis prophylaxis according to institutional practice or patients on
             aspirin may be enrolled.

          2. Patients in whom citrate anticoagulation is contraindicated such as patients with a
             known allergy to citrate or who have experienced adverse events associated with
             citrate products including patients with a prior history of citrate toxicity or
             patients with uncorrected severe hypocalcemia (whether in the context of current
             citrate administration or due to the underlying disease state).

          3. Patients who are not candidates for CRRT.

          4. Patients who are receiving extracorporeal membrane oxygenation (ECMO) therapy.

          5. Patients with severe coagulopathy [i.e., platelets &lt; 30,000/mm3, international
             normalized ratio (INR) &gt; 2, partial thromboplastin time (PTT) &gt; 50 seconds] including
             severe thrombocytopenia (platelets &lt; 30,000/mm3), HIT (heparin induced
             thrombocytopenia), ITP (idiopathic thrombocytopenia purpura), and TTP (thrombotic
             thrombocytopenia purpura) should not be enrolled in the trial.

          6. Patients with fulminant acute liver failure or acute on chronic liver failure as
             documented by a Child-Pugh Liver Failure Score &gt; 10.

          7. Patients with refractory shock associated persistent, worsening with lactic acidosis
             (lactate &gt; 4 mmol/L). However, patients with improving subsequent serum lactate
             levels may be enrolled.

          8. Patients unlikely to survive at least 72 hours.

          9. Female patients who are pregnant, lactating, or planning to become pregnant during
             the study period.

         10. Patients who are currently participating in another interventional clinical study.

         11. Patients with a medical condition that may interfere with the study objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anh T Nguyen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baxter Healthcare Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Arcaroli, MS</last_name>
    <email>jennifer_arcaroli@baxter.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Judd, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tuscan</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bijin Thajudeen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anjay Rastogi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Justin Belcher, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Connor, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cybele Ghossein-Hoseen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jason Stubbs, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Javier Neyra, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Herr, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess (Harvard)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bradley Denker, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Juncos, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sevag Demirjian, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sean Bagshaw, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 4, 2017</lastchanged_date>
  <firstreceived_date>July 29, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Regional Citrate Anticoagulation (RCA)</keyword>
  <keyword>Continuous Renal Replacement Therapy (CRRT)</keyword>
  <keyword>Acute Kidney Injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Citric Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
